Exscientia (NASDAQ:EXAI – Get Rating) had its target price upped by Morgan Stanley from $20.00 to $21.00 in a research report sent to investors on Monday morning, MarketBeat.com reports. The firm currently has an equal weight rating on the stock.
Separately, Zacks Investment Research lowered shares of Exscientia from a buy rating to a hold rating in a research report on Wednesday, March 9th.
Shares of NASDAQ:EXAI opened at $15.08 on Monday. The company has a debt-to-equity ratio of 0.01, a current ratio of 12.72 and a quick ratio of 12.71. Exscientia has a 12-month low of $11.10 and a 12-month high of $30.38. The stock’s fifty day moving average is $15.68.
Institutional investors have recently modified their holdings of the stock. Davidson Kempner Capital Management LP bought a new position in Exscientia during the fourth quarter valued at approximately $198,000. Citigroup Inc. bought a new stake in shares of Exscientia during the 4th quarter valued at $298,000. TD Asset Management Inc. bought a new stake in shares of Exscientia during the 4th quarter valued at $402,000. Squarepoint Ops LLC purchased a new position in Exscientia during the fourth quarter valued at $712,000. Finally, Russell Investments Group Ltd. purchased a new position in Exscientia during the fourth quarter valued at $1,002,000. Institutional investors own 16.10% of the company’s stock.
About Exscientia (Get Rating)
Exscientia plc, an artificial intelligence-driven pharmatech company, engages in discovering, designing, and developing drugs. The company offers end-to-end solution of artificial intelligence (AI) and technologies for target identification, drug candidate design, translational models, and patient selection.
- Get a free copy of the StockNews.com research report on Exscientia (EXAI)
- OrganiGram’s Turnaround Begins To Blossom
- Three Dividend Stocks With Growth Potential
- Exelon Stock Still Has Extraordinary Upside
- Ross Stores On The Verge Of Major Rally
- Greenbrier Companies Stock has Green in its Future
Receive News & Ratings for Exscientia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exscientia and related companies with MarketBeat.com's FREE daily email newsletter.